New Investigational Drug For Slowing Down Progression Of Early Alzheimer’s
Research Centre: Neuro Trials Victoria
Location: Neuro Trials Victoria, 1 Beck Court, Noble Park, VIC, 3174
Lead Doctor: Dr Peter Farnbach, Prof. David Barton
Ethics Committee: This study has been reviewed and approved by St Vincent’s Hospital Sydney Human Research Ethics Committee
Early stage Alzheimer’s causes a slight but noticeable decline in mental abilities, such as memory loss and impaired thinking. People with early stage Alzheimer’s have a much higher risk of going on to develop dementia.
The clinical study will assess how safe and effective an investigational medication is at slowing the progression of early (also known as ‘prodromal’) or mild Alzheimer’s disease.
This study seeks men and women aged 50-90 who currently have early stage Alzheimer’s. Participants are required to attend multiple study visits over a 3 year period. The study visits will initially be every 4 weeks, and then fortnightly. Some of the study visits can be done in your own home with a visiting nurse. You will be reimbursed for travel, parking, meals and other costs associated with participating in the study.
- You will get very good oversight by a professional medical team
- You will be helping to advance medical research regarding early stage Alzheimer’s
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 50 -90 who have early stage Alzheimer’s
- Have a family member or friend who can act as a study partner throughout the duration of the study and attend study visits with the participant at least 7 times
- Suffering from early stage Alzheimer’s